{"id":107538,"date":"2020-05-23T19:03:16","date_gmt":"2020-05-24T02:03:16","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/05\/remdesivir-for-the-treatment-of-covid-19-preliminary-report"},"modified":"2020-05-23T19:03:16","modified_gmt":"2020-05-24T02:03:16","slug":"remdesivir-for-the-treatment-of-covid-19-preliminary-report","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/05\/remdesivir-for-the-treatment-of-covid-19-preliminary-report","title":{"rendered":"Remdesivir for the Treatment of Covid-19 \u2014 Preliminary Report"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/remdesivir-for-the-treatment-of-covid-19-preliminary-report.jpg\"><\/a><\/p>\n<p>A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.<sup><a data-behavior=\"ShowPopupTip\" data-popup-content-ids=\"ref1\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007764?query=featured_home&cookieSet=1\">1<\/a><\/sup> Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious.<sup><a data-behavior=\"ShowPopupTip\" data-popup-content-ids=\"ref2,ref3\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007764?query=featured_home&cookieSet=1\">2,3<\/a><\/sup> Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV),<sup><a data-behavior=\"ShowPopupTip\" data-popup-content-ids=\"ref4,ref5,ref6,ref7\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007764?query=featured_home&cookieSet=1\">4\u20137<\/a><\/sup> was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro.<sup><a data-behavior=\"ShowPopupTip\" data-popup-content-ids=\"ref8\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007764?query=featured_home&cookieSet=1\">8<\/a><\/sup> In addition, in nonhuman primate studies, remdesivir initiated 12 hours after inoculation with MERS-CoV<sup><a data-behavior=\"ShowPopupTip\" data-popup-content-ids=\"ref9,ref10\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007764?query=featured_home&cookieSet=1\">9,10<\/a><\/sup> reduced lung virus levels and lung damage.<\/p>\n<p>To evaluate the clinical efficacy and safety of putative investigational therapeutic agents among hospitalized adults with laboratory-confirmed Covid-19, we designed an adaptive platform to rapidly conduct a series of phase 3, randomized, double-blind, placebo-controlled trials. Here, we describe the preliminary results of the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), in which we evaluated treatment with remdesivir as compared with placebo.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.1 Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious.2,3 Remdesivir (GS-5734), an inhibitor of the [\u2026]<\/p>\n","protected":false},"author":461,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-107538","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/107538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/461"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=107538"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/107538\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=107538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=107538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=107538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}